GALECTO, INC. GLTO 深 滬
已收盤 12-24 16:00:00 美东时间
29.49
+0.410
+1.41%
華盛通- 最 高30.00
- 今 開28.835
- 成交量 1.79万股
- 最 低 28.835
- 昨 收 29.08
- 總市值 3899.76万
- 52周最高 33.60
- 市盈率 靜 --
- 換手率 1.36%
- 52周最低 2.01
- 委 比 -99.52%
- 總股本 132.24万
- 歷史最高 449.75
- 量 比 0.34
- 振 幅 4.01%
- 歷史最低 2.01
- 每 手 1
- 風險率 6.95%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅2566.67%！Ascendiant Capital上调GRI Bio目标价至36美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从35美元升至36美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.75美元升至8美元
12-09 10:32
Guggenheim Maintains Buy on Galecto, Raises Price Target to $36
Guggenheim analyst Brad Canino maintains Galecto (NASDAQ:GLTO) with a Buy and raises the price target from $32 to $36.
12-08 21:35
美股大行评级 | 超配！BETA、BillionToOne获多家机构首予评级；摩根大通上调阿斯麦目标价升至1275美元
今日重点评级关注：RBC Capital：上调Neumora Therapeutics评级至"跑赢大市"，目标价从4美元升至7美元；HC Wainwright & Co.：维持ProMIS Neurosciences"买入"评级，目标价从4美元升至18美元
12-02 09:50
Guggenheim Initiates Coverage On Galecto with Buy Rating, Announces Price Target of $32
Guggenheim analyst Brad Canino initiates coverage on Galecto (NASDAQ:GLTO) with a Buy rating and announces Price Target of $32.
12-01 20:49
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers MSP Recovery (NASDAQ:MSPR) shares rose 93.0% to $0.61 during Tuesday's...
11-11 20:07
Market-Moving News for November 10th
PLUG: 12% | Plug Power shares are trading higher after signing a non-binding LOI to monetize electricity rights in New York and another location and partner with a U.S. data center developer. GLTO: 400% |
11-10 20:28
Galecto Acquires Damora Therapeutics, Pays ~$284.9M In Form Of Private Placement Of Series C Non-Voting Convertible Preferred Stock
Galecto, Inc. ("Galecto") today announced the completion of the acquisition of Damora Therapeutics, Inc. ("Damora"), a privately held biotechnology company advancing a pipeline of antibody therapeutics aimed at
11-10 20:04
Galecto Reports Third Quarter 2025 Operating and Financial Results
Galecto, Inc. announced its third-quarter 2025 results, highlighting positive FDA feedback on GB3226, a dual inhibitor targeting AML, with plans to submit an IND in early 2026. Cash reserves stood at $7.6 million, sufficient for near-term GB3226 development. R&D expenses rose by $0.3 million, while G&A costs fell by $1.0 million. The company reported a net loss of $3.1 million, narrowed from $3.9 million the prior year. Galecto emphasizes its com...
11-06 21:30
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Xenetic Biosciences (NASDAQ:XBIO) stock moved upwards by 137.1% to $10...
10-09 01:06
Nasdaq Gains 150 Points; US Mortgage Applications Decline
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more ...
10-08 22:22
